Literature DB >> 19270498

TRAIL induces endocytosis of its death receptors in MDA-MB-231 breast cancer cells.

Yaqin Zhang1, Tatsushi Yoshida, Baolin Zhang.   

Abstract

TNF-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent that selectively induces apoptosis in cancer cells over normal cells. Here, we show that TRAIL undergoes rapid endocytosis with its death receptors DR4, and likely DR5, in MDA-MB-231 human breast cancer cells. The internalized DR4, but not DR5, is cleaved in a caspase-dependent manner. Blockade of receptor internalization does not prevent caspase activation, but rather enhances apoptosis after TRAIL treatment. TRAIL-induced receptor endocytosis appears to undermine its ability in inducing apoptosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19270498     DOI: 10.4161/cbt.8.10.8141

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  20 in total

1.  Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.

Authors:  Karen Bräutigam; Julia Biernath-Wüpping; Dirk O Bauerschlag; Constantin S von Kaisenberg; Walter Jonat; Nicolai Maass; Norbert Arnold; Ivo Meinhold-Heerlein
Journal:  J Cancer Res Clin Oncol       Date:  2010-09-29       Impact factor: 4.553

2.  Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells.

Authors:  N Mazurek; J C Byrd; Y Sun; M Hafley; K Ramirez; J Burks; R S Bresalier
Journal:  Cell Death Differ       Date:  2011-09-23       Impact factor: 15.828

Review 3.  Ceramide-orchestrated signalling in cancer cells.

Authors:  Samy A F Morad; Myles C Cabot
Journal:  Nat Rev Cancer       Date:  2012-12-13       Impact factor: 60.716

4.  Monocyte chemotactic protein-induced protein-1 enhances DR5 degradation and negatively regulates DR5 activation-induced apoptosis through its deubiquitinase function.

Authors:  You-Take Oh; Guoqing Qian; Jiusheng Deng; Shi-Yong Sun
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

Review 5.  The TRAIL to targeted therapy of breast cancer.

Authors:  Monzur Rahman; Janet G Pumphrey; Stanley Lipkowitz
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

Review 6.  Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer.

Authors:  Ufuk Mert; Ahter Dilsad Sanlioglu
Journal:  Cell Mol Life Sci       Date:  2016-08-10       Impact factor: 9.261

7.  TRAIL and vitamins: opting for keys to castle of cancer proteome instead of open sesame.

Authors:  Ammad Ahmad Farooqi; Shahzad Bhatti; Muhammad Ismail
Journal:  Cancer Cell Int       Date:  2012-06-06       Impact factor: 5.722

8.  Novel HTS strategy identifies TRAIL-sensitizing compounds acting specifically through the caspase-8 apoptotic axis.

Authors:  Darren Finlay; Robyn D Richardson; Lisa K Landberg; Amy L Howes; Kristiina Vuori
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

9.  Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells.

Authors:  Jun-Jie Chen; H-C Jennifer Shen; Leslie A Rivera Rosado; Yaqin Zhang; Xu Di; Baolin Zhang
Journal:  Oncotarget       Date:  2012-08

10.  TRAIL induces apoptosis in oral squamous carcinoma cells--a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5.

Authors:  Jun-Jie Chen; Constantinos M Mikelis; Yaqin Zhang; J Silvio Gutkind; Baolin Zhang
Journal:  Oncotarget       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.